Timor Baasov Selected Research

Aminoglycosides

1/2017	Characterization of new-generation aminoglycoside promoting premature termination codon readthrough in cancer cells.
9/2015	Structural basis for selective targeting of leishmanial ribosomes: aminoglycoside derivatives as promising therapeutics.
1/2014	Designer aminoglycosides that selectively inhibit cytoplasmic rather than mitochondrial ribosomes show decreased ototoxicity: a strategy for the treatment of genetic diseases.
1/2014	Aminoglycoside-Induced Premature Stop Codon Read-Through of Mucopolysaccharidosis Type I Patient Q70X and W402X Mutations in Cultured Cells.
1/2014	Therapy strategies for Usher syndrome Type 1C in the retina.
8/2013	Identification of the molecular attributes required for aminoglycoside activity against Leishmania.
3/2013	Development of generic immunoassay for the detection of a series of aminoglycosides with 6'-OH group for the treatment of genetic diseases in biological samples.
12/2012	Increased selectivity toward cytoplasmic versus mitochondrial ribosome confers improved efficiency of synthetic aminoglycosides in fixing damaged genes: a strategy for treatment of genetic diseases caused by nonsense mutations.
11/2011	Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54.
4/2011	Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Timor Baasov Research Topics

Disease

17	Inborn Genetic Diseases (Disease, Hereditary) 01/2017 - 12/2006
6	Mucopolysaccharidosis I (Hurler Syndrome) 04/2016 - 05/2009
5	Cystic Fibrosis (Mucoviscidosis) 04/2016 - 05/2009
4	Usher Syndromes (Usher Syndrome) 04/2016 - 11/2007
2	Leishmaniasis 09/2015 - 08/2013
2	Ototoxicity 04/2014 - 01/2014
2	Lysosomal Storage Diseases (Lysosomal Storage Disease) 03/2014 - 01/2012
2	Rett Syndrome (Rett's Disorder) 04/2011 - 01/2011
2	Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker) 06/2010 - 05/2009
1	Neoplasms (Cancer) 01/2017
1	Body Weight (Weight, Body) 03/2016
1	Glucose Intolerance 03/2016
1	Visceral Leishmaniasis (Kala Azar) 09/2015
1	Disease Progression 03/2014
1	Retinal Degeneration 01/2014
1	type 1C Usher syndrome 01/2014

Drug/Important Bio-Agent (IBA)

17	AminoglycosidesIBA 01/2017 - 12/2006
15	Nonsense Codon (Nonsense Mutation)IBA 01/2017 - 11/2007
6	Gentamicins (Gentamicin)FDA LinkGeneric 01/2017 - 05/2009
5	Anti-Bacterial Agents (Antibiotics)IBA 09/2015 - 09/2007
3	antibiotic G 418IBA 01/2017 - 03/2013
3	DNA (Deoxyribonucleic Acid)IBA 04/2016 - 05/2009
3	Iduronidase (alpha-L-Iduronidase)IBA 03/2014 - 01/2012
1	Glucose (Dextrose)FDA LinkGeneric 03/2016
1	gamma-Aminobutyric Acid (GABA)IBA 03/2016
1	Paromomycin (Paromomycin Sulfate)FDA LinkGeneric 09/2015
1	Proteins (Proteins, Gene)FDA Link 01/2014
1	atalurenIBA 01/2014
1	Zinc Finger NucleasesIBA 01/2014
1	apramycinIBA 08/2013
1	Biological ProductsIBA 03/2013
1	GlycosaminoglycansIBA 01/2012
1	Terminator Codon (Termination Codon)IBA 09/2011
1	Methyl-CpG-Binding Protein 2IBA 01/2011

Therapy/Procedure

7	Therapeutics 01/2017 - 04/2011